| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 31722-0262-01 | 31722-0262 | LENALIDOMIDE | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 59572-0501-21 | 59572-0501 | Pomalidomide | Pomalyst | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 59572-0504-00 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 59572-0502-00 | 59572-0502 | Pomalidomide | Pomalyst | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 63304-0045-01 | 63304-0045 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 12, 2023 | In Use | |
| 63304-0042-01 | 63304-0042 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
| 59572-0504-21 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 82293-0006-10 | 82293-0006 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 6, 2026 | In Use | |
| 59651-0195-21 | 59651-0195 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Oct 30, 2020 | In Use | |
| 82293-0008-10 | 82293-0008 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 6, 2026 | In Use | |
| 59651-0344-07 | 59651-0344 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 73043-0039-01 | 73043-0039 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 31, 2026 | In Use | |
| 00378-1940-01 | 00378-1940 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 00480-1244-21 | 00480-1244 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2022 | In Use | |
| 00378-1936-28 | 00378-1936 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 70710-1032-01 | 70710-1032 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 73043-0040-28 | 73043-0040 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 31, 2026 | In Use | |
| 31722-0262-21 | 31722-0262 | LENALIDOMIDE | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 59651-0196-01 | 59651-0196 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Oct 30, 2020 | In Use | |
| 59572-0220-16 | 59572-0220 | Thalidomide | Thalomid | 200.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 20, 2003 | In Use | |
| 59572-0205-17 | 59572-0205 | Thalidomide | Thalomid | 50.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Dec 1, 2010 | In Use | |
| 70771-1677-07 | 70771-1677 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 69097-0384-81 | 69097-0384 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sep 20, 2021 | In Use | |
| 65597-0406-01 | 65597-0406 | fam-trastuzumab deruxtecan-nxki | Enhertu | 100.0 mg/5mL | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I Inhibitor | Intravenous | Dec 20, 2019 | In Use |
Found 12250 results — Export these results
Home